News roundup [abridged versions appear in the paper journal]

Pfizer will not apply for a licence for sildenafil for women

BMJ 2004; 328 doi: 10.1136/bmj.328.7439.542 (Published 4 March 2004)
Cite this as: BMJ 2004;328:542.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Susan Mayor
  1. London

    Pfizer, the company that developed the phosphodiesterase inhibitor sildenafil (Viagra), reported last week that efficacy results in women with what has been termed female sexual arousal disorder had been inconclusive and would not support filing for regulatory approval to use the drug in this indication.

    In a statement, Pfizer said that several large scale, placebo controlled studies including about 3000 women with female sexual arousal disorder showed inconclusive results on the efficacy of sildenafil (www.pfizer.com). The disorder is defined by the American Foundation for Urological Diseases as distress caused by a persistent inability to attain or maintain sexual excitement.

    Dr Joe Feczko, president of worldwide development with the company, said in the statement: “FSAD [female sexual arousal disorder] …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular